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Osami Honjo, MD, PhD*,‡, and Vivek Rao, MD†,‡The new-generation continuous-ﬂow left ventricular assistdevices (VAD) have dramatically improved clinical out-
comes of adult patients with end-stage heart failure in the
current era.1 In the adult population, multiple devices are
available as a long-term bridge to transplantation2 and as
destination therapy1 with low device-related morbidity and
mortality. On the contrary, long-term mechanical circulatory
support options in the pediatric population have been
extremely limited. Pediatric patients with end-stage heart
failure have traditionally been supported with extracorporeal
membrane oxygenation with dismal success rate for bridge to
transplantation owing to extracorporeal membrane oxygen-
ation–related complications.3 Recent clinical application of the
EXCOR pediatric assist device (Berlin Heart), a paracorporeal
pulsatile-ﬂow VAD, has substantially improved the survival of
the patients who were bridged to transplantation with VAD.4
Nonetheless, approximately one-third of the patients who are
supported with the Berlin Heart have embolic stroke and
other major complications.4 Adult-sized VADs have been used
in adolescents and some selected patients with a high rate of
bridge to transplantation5; however, the mismatch between
device and body sizes precludes routine use of adult-sized
VADs in the pediatric population.
The HeartWare ventricular assist system (HVAD) (Heart-
Ware, Framingham, MA) is a new-generation, small,
centrifugal, continuous-ﬂow pump. This device is designed
to be implanted directly into the left ventricle and positioned
within the pericardial space without requiring a subdiaph-
ragmatic pocket. The initial clinical trial using HVAD showed
90.7% success rate (transplanted or alive) with reasonable
incidence of stroke (12%) in patients who were supported
with HVAD, which was equivalent to that of the commercially
available devices.6 HVAD is particularly attractive for the
pediatric population because of the small pump size and
integrated short inﬂow cannula, which allows complete
intrapericardial implantation. In Canada, HVAD has been
implanted since 2010, and the ﬁrst HVAD implantation wasfront matter r 2014 Elsevier Inc. All rights reserved.
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the surgical principles and techniques of HVAD implantation
in the pediatric population are discussed.The HeartWare system
The designs and structure of HVAD device are detailed
elsewhere.7 Brieﬂy, The HeartWare system consists of an
implantable centrifugal continuous-ﬂow pump (HVAD), an
external controller, and external power sources. HVAD
consists of a blood pump (displaced volume ¼ 50 mL;
weight ¼ 160 g) with an integrated short inﬂow cannula, a
10-mm gel-impregnated polyester outﬂow graft with strain
relief and a percutaneous driveline (Fig. 1). The device
employs a hybrid hydromagnetic impeller suspension
system, which allows contact-free operation and smaller
size and minimizes friction, heat generation, and component
wear.7 The maximal pump ﬂow is 10 L/min.Preparation and Exposure
The patient is anesthetized with standard medications and is
placed on mechanical ventilation. Catheters are inserted in
the radial artery and the internal jugular vein to continuously
monitor arterial and central venous pressure. In our
institution, a near-infrared spectroscopy probe is routinely
placed in the forehead of the patient to monitor cerebral
blood ﬂow trends. A transesophageal echocardiogram (TEE)
is not routinely performed before HVAD insertion if the
preoperative transthoracic echocardiogram clearly shows the
presence or absence of a patent foramen ovale. A TEE is
performed before initiation of cardiopulmonary bypass if the
status of the atrial septum is unclear. The degree of aortic
insufﬁciency is also evaluated before surgery. If the patient
has had previous sternotomies, preoperative ultrasound is
routinely performed to measure the size of both neck and
femoral arteries and veins. The groin is prepared bilaterally.
Groin vessels are not exposed before the sternotomy unless
clear high-risk appearance is seen on cross-sectional
imaging. In smaller patients (o25 kg), the right neck may
be prepared. A standard median sternotomy is made and the
pericardium opened. The patient is systemically heparinized
aiming for an activated clotting time of more than 400
seconds (Figs. 2-8).
Figure 1 HVAD consists of a small centrifugal blood pump with an integrated short inﬂow cannula, a 10-mm polyester outﬂow graft with
strain relief, and a percutaneous driveline.
Operative Technique
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Figure 2 (A) A standard median sternotomy is made. (B) CPB is initiated with standard ascending aortic and single right atrial cannulation. A
dual-stage cannula is used for nearly adult-sized patients, and a large right-angled metal-tip cannula is used in relatively small patients
(o50 kg). The aortic cannula should be placed at the distal ascending aorta or proximal aortic arch to place a partial occluding clamp on the
ascending aorta. CPB ¼ cardiopulmonary bypass.
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Figure 2 (Continued) (C) Bicaval cannulation is performed when the patient has a PFO or requires concomitant intracardiac procedures. The
right-angled metal-tip venous cannula is our preferred cannula. PFO ¼ patent foramen ovale.
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Figure 3 Placement of sewing ring. The LV apex is exposed by placing sponges in the pericardial cavity underneath the ventricle. According to
the planned location of LV apical cannula position, which is approximately 1-2 cm anterior to the apical dimple, the location of sewing ring
placement is decided. The inﬂow cannula has to point the mitral valve and be parallel to the intraventricular septum. Pledgeted 3-0
polypropylene or 2-0 Ti-Cron sutures are placed around the planned apical incision and are passed through the sewing ring. The sewing ring
should be positioned in a way that its screw can be easily accessible after cannulation. LV ¼ left ventricle.
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Figure 4 LV apex incision. (A) The initial incision is made with a No. 11-blade scalpel. LV ¼ left ventricle; LAD ¼ left anterior descending.
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Figure 4 (Continued) (B) followed by scissors or No. 15 blade scalpel or both inside the sewing ring.
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Figure 4 (Continued) (C) The LV cavity is carefully inspected for potential thrombi. Thrombus should be completely removed before inﬂow
cannula placement. Care is also taken to remove all trabeculae that potentially obstructs the inﬂow cannula. LV ¼ left ventricle.
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Figure 4 (Continued) (D) An apical coring tool can be used to complete the removal of myocardial core. LAD ¼ left anterior descending.
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Figure 5 Placement of HVAD inﬂow cannula. Before insertion, a clamp is placed on the outﬂow graft. Insert the inﬂow cannula to the LV. Once
the cannula is entirely inserted (A), the sewing ring is tightened using the sewing ring wrench until a click sound is heard. LV ¼ left ventricle.
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Figure 5 (Continued) (B). Complete hemostasis around the sewing ring should be achieved before moving onto the next step.
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Figure 6 Placement of the outﬂow graft. The outﬂow graft is gently stretched and cut in an appropriate length. Care is taken to not leave it too
long or too short to avoid kinking or overstretching. A partial occluding clamp is placed on the ascending aorta. Care is taken not to place the
clamp too close to the origin of the right coronary artery. The anastomosis between the ascending aorta and the outﬂow graft is made with a
4-0 or 5-0 polypropylene continuous suture. Pledgets are typically not used in this anastomosis. After completing the anastomosis, the
location of the driveline exit is decided. Using the specially designed tunneler, the driveline is taken out of the chest cavity through the skin
and is connected to the controller.
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Figure 7 Deairing process. Deairing is performed under TEE guidance. Ventilation is started and the patient is placed in the Trendelenburg
position. The outﬂow cannula is clamped close to the aortic anastomosis. A large needle is placed in the graft to deair the graft.
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Figure 8 (A) Before chest closure, the entire graft and HVAD pump are wrapped with GORE-TEX membranes (W.L. Gore CO, Newark, DE).
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Figure 8 (Continued) (B) This facilitates dissection and potentially protects the outﬂow graft at the time of sternal reentry. After the chest
closure, only the driveline comes out through the skin in the subcostal region.
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Table The Clinical Proﬁle of 4 Patients Who Were Supported by HVAD in The Hospital for Sick Children
Patient Age (y) Body Weight (kg) Diagnosis Duration (d) Outcome
1 13 60 Dilated cardiomyopathy 22 Transplanted
2 15 56 Dilated cardiomyopathy 5 Transplanted
3 15 47 Drug-induced cardiomyopathy 640 (still on HVAD) Listed
4 15 80 Myocardial failure after arterial switch 76 Transplanted
HeartWare VAD in Children 95Weaning From Cardiopulmonary
Bypass
Once the implant procedure is completed, the TEE probe is
inserted and deairing is performed under TEE guidance.
Ventilation is started and the patient is placed in a
Trendelenburg position. The outﬂow cannula is clamped
close to the aortic anastomosis. A large needle is placed in
the graft to deair the graft (Fig. 7). Low-dose milrinone is
routinely administered. For the patients with reduced right
ventricular function, epinephrine or inhaled nitric oxide or
both are used.Pediatric HVAD Experience in
Literature
Literature regarding HVAD implantation in children and
adolescents is quite limited. Miera et al8 reported the largest
series of HVAD implantation in children, which consisted of
7 patients between 6 and 16 years of age. The smallest
patient in their series was a 6-year-old child with a body
weight of 17 kg. This patient had been on HVAD for 136
days with no major complication. Of the 7 patients,
6 underwent successful transplantation and 1 patient was
still on HVAD at the time of publication. There was no major
thromboembolic complication and 1 patient had an acquired
von Villebrand factor deﬁcit and subsequent hemorrhagic
pericardial effusion. Kirklin et al9 reported a 9-year-old
patient with a body weight of 42.8 kg who was supported
with HVAD for 60 days without any major complication.
The patient underwent successful transplantation.Experience in the Hospital for
Sick Children
The ﬁrst implantation of HVAD in The Hospital for Sick
Children was in December 2011. Since then, 4 patients have
been supported by HVAD (Table). The minimal body weight
in our experience was 47 kg. There were no majorcomplications during HVAD support. Overall, 3 patients
underwent transplantation and 1 patient has been supported
more than 1.5 years as the bridge to decision making.Summary
The new-generation, small, continuous-ﬂow pump, HVAD is
an attractive device for the pediatric population because of
its small size that allows complete intrapericardial implanta-
tion. Our limited experience in adolescents is encouraging
and we expect to expand the indication of HVAD
implantation for smaller children. The technical modiﬁcation
and protection of the HVAD device and graft by GORE-TEX
membrane facilitate the dissection and lower the risk at chest
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